pharmaphorum
JANUARY 27, 2022
Walter Greenleaf, PhD, neuroscientist and digital health expert at Stanford University’s Virtual Human Interaction Lab, tells us about the new book Applied Virtual Reality in Healthcare: Case Studies and Perspectives and why he and his co-authors gathered insights from some of the most prominent figures in the field of medical extended reality (XR).
Pharma Times
JANUARY 25, 2022
The UCL study will evaluate the safety and effectiveness of MTL-CEBPA in combination with second line standard of care sorafenib versus the use of sorafenib in isolation
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eye on FDA
JANUARY 26, 2022
FDA’s Office of Prescription Drug Promotion (OPDP) issued the first regulatory action letter for 2022. This one has some notable characteristics. As has been frequently noted, enforcement actions by OPDP have diminished considerably over the years. Another characteristic of recent enforcement actions over the past several years is that smaller, less well-known companies have mostly been the recipients of letters from OPDP.
Drug Patent Watch
JANUARY 24, 2022
Annual Drug Patent Expirations for ESBRIET Esbriet is a drug marketed by Genentech Inc and is included in two NDAs. It is available from one supplier. There are twenty-one patents…. The post New patent expiration for Genentech Inc drug ESBRIET appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JANUARY 24, 2022
In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with AZ’s Joris Silon to discuss unmet needs in the condition. “Many times, I have talked to nephrologists who take care of patients with chronic kidney disease in the later stages, and they have a very simple message – and that is, if we really want to do something for these patients then we need to intervene earlier,” says Joris Silon, se
Pharma Times
JANUARY 24, 2022
The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Marketing Network
JANUARY 27, 2022
Tune in to the Pharma Marketing Network and industry experts Novartis, UCB, GSK and others, for a fireside talk on hot topics around what has changed in the last year and how to align your pharma marketing strategies accordingly. Three Panels: . Engaging Oncologists in 2022. Emerging Digital Channels and Navigating the Social Landscape: What’s Hot, What’s Not, What’s the Next Big Thing.
pharmaphorum
JANUARY 26, 2022
Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator cleared the company’s lead TCR Kimmtrak (tebentafusp; formerly IMCgp100 ) – a bispecific T cell engager (BiTE) that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal me
Pharma Times
JANUARY 26, 2022
COVID-19 vaccine luminaries Pfizer and BioNTech study will examine data from the current booster and consider need for specific Omicron jab
Outsourcing Pharma
JANUARY 24, 2022
The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
JANUARY 28, 2022
Today’s guest post comes from Fiza Bari, Senior Solutions Consultant and GTM Liaison at MMIT. Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. It's a moderated discussion with payers on how the changing market might impact their management strategies in immunology.
pharmaphorum
JANUARY 28, 2022
Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug as post-surgery (adjuvant) therapy for renal cell carcinoma (RCC). Adjuvant treatment moves use of the drug into patients with earlier-stage cancer, a key strategy for Merck and other cancer immunotherapy companies as it expands the pool of patients eligible for treatment.
Pharma Times
JANUARY 24, 2022
Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.
Outsourcing Pharma
JANUARY 25, 2022
The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientificâs Nantheia ATL5, a candidate for treating opioid use disorder.
Drug Channels
JANUARY 25, 2022
Super Bowl LVI is on the horizon. Time for some blow-out beer commercials, occasionally interrupted by a football game. But who needs a Super Bowl party when you can tackle this month’s selection of notable news stories, intercepted for you from the Drug Channels gridiron: Offsides : A shocking update about the gross-to-net bubble for insulin Trick Play : OptumRx trolls us Fumble : High-deductible health plans foul out with patients Offensive Lines : The 340B program’s unstoppable growth Plus, t
pharmaphorum
JANUARY 24, 2022
A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.
Pharma Times
JANUARY 26, 2022
Ipsen and Domainex collaboration will provide an exclusive licence to develop innovative inhibitors and pioneering cancer treatments
Outsourcing Pharma
JANUARY 26, 2022
A leader from Elligo Health Research (a SCOPE 2022 exhibitor ) discusses flaws in traditional recruitment approaches and offers up some fresh new ideas.
NY Times
JANUARY 26, 2022
It never quite fit in your wallet, so it’s no surprise you may have misplaced it by now.
pharmaphorum
JANUARY 25, 2022
The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. To demonstrate how quickly the digital therapeutics space is developing, it is easiest to state that the first such therapy was approved in 2018 and since that point the annual investment in the space has more than doubled in the intervening years.
Pharma Times
JANUARY 25, 2022
Novartis UK has announced that the MHRA has given a positive scientific opinion for the investigational treatment, asciminib
Outsourcing Pharma
JANUARY 25, 2022
Am expert from the CRO discusses unique challenges associated with running clinical trials that stretch across national boarders and how to conquer them.
Drug Patent Watch
JANUARY 28, 2022
Annual Drug Patent Expirations for BRAFTOVI Braftovi is a drug marketed by Array Biopharma Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Array Biopharma drug BRAFTOVI appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 25, 2022
Oskar Möbert, Vice President OpenData Europe at Veeva Systems, tells us how they are reimagining customer reference data to boost pharma rep productivity, enable more personalised engagement, and increase patient reach. The medical landscape is generally becoming more complex, both in terms of the range of stakeholders involved in patient care and the rapid explosion of engagement channels. “Our customers need to make decisions based on insights powered by a deep understanding of their tar
Pharma Times
JANUARY 27, 2022
MHRA awards a positive scientific opinion for voxelotor–a once-daily tablet for the treatment of haemolytic anaemia
Outsourcing Pharma
JANUARY 28, 2022
A representative from IQVIA discusses the particulars of the US agencyâs new draft document and shares what it might mean for clinical trial data evaluation.
Drug Patent Watch
JANUARY 28, 2022
Annual Drug Patent Expirations for XARELTO Xarelto is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There are four patents…. The post New patent for Janssen Pharms drug XARELTO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 26, 2022
We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States. So, what can we do to keep home-grown science on European soil? From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial role in the global response to COVID-19.
Pharma Times
JANUARY 28, 2022
Collaboration of big hitters and introduction of innovation sparks pioneering HIV vaccination trial
Outsourcing Pharma
JANUARY 26, 2022
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
Drug Patent Watch
JANUARY 28, 2022
Annual Drug Patent Expirations for VALTOCO Valtoco is a drug marketed by Neurelis Inc and is included in one NDA. There are five patents protecting this drug. VALTOCO drug price…. The post New patent for Neurelis Inc drug VALTOCO appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JANUARY 27, 2022
Akili Interactive has agreed a merger with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp I in a deal that will take it into public hands with a valuation of around $1 billion. The digital health company, which developed the first prescription gaming app to be approved by the FDA, will swell its coffers by more than $410 million gross once the deal go through.
Pharma Times
JANUARY 28, 2022
Gene luminaries Oxford Biomedica reach agreement with Homology Medicines to develop super group
Pharma Mirror
JANUARY 28, 2022
Singapore, Asia’s integrated healthcare company, Clearbridge Health Limite is pleased to announce that Labnovation Technologies, Inc.’s (“Labnovation”) COVID-19 Antigen Rapid (“ART”) Test Kit, which is imported by Clearbridge and registered for use in the Philippines, has been recently approved by the Food and Drug Administration (“FDA”) of the Philippines for self-testing.
Drug Patent Watch
JANUARY 28, 2022
Annual Drug Patent Expirations for NUBEQA Nubeqa is a drug marketed by Bayer Healthcare and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Bayer Healthcare drug NUBEQA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
135 
Let's personalize your content